Detalhe da pesquisa
1.
Bifurcation PCI with a hybrid strategy with drug- eluting balloons versus a stepwise provisional two- stent strategy: Rationale and design of the hybrid DEB study.
Am Heart J
; 266: 168-175, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37806333
2.
Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial.
Circulation
; 143(22): 2143-2154, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33820424
3.
Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design.
Am Heart J
; 246: 32-43, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34990582
4.
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Lancet
; 395(10233): 1374-1381, 2020 04 25.
Artigo
Inglês
| MEDLINE | ID: mdl-32334703
5.
Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus-AIDA sub-study.
Catheter Cardiovasc Interv
; 98(4): 713-720, 2021 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33118696
6.
Prehospital risk stratification in patients with chest pain.
Emerg Med J
; 38(11): 814-819, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34373266
7.
Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.
Lancet
; 393(10175): 987-997, 2019 03 09.
Artigo
Inglês
| MEDLINE | ID: mdl-30827782
8.
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.
N Engl J Med
; 376(24): 2319-2328, 2017 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28402237
9.
Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.
Catheter Cardiovasc Interv
; 95(1): 89-96, 2020 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30968559
10.
A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
Lancet
; 391(10119): 431-440, 2018 02 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29203070
11.
Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.
Eur Heart J
; 37(3): 229-40, 2016 Jan 14.
Artigo
Inglês
| MEDLINE | ID: mdl-26405232
12.
Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands.
Neth Heart J
; 23(3): 161-5, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25626696
13.
Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
Lancet
; 381(9867): 651-60, 2013 Feb 23.
Artigo
Inglês
| MEDLINE | ID: mdl-23374650
14.
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
N Engl J Med
; 363(2): 136-46, 2010 Jul 08.
Artigo
Inglês
| MEDLINE | ID: mdl-20554978
15.
Safety and efficacy of everolimus- versus sirolimus-eluting stents: a systematic review and meta-analysis of 11 randomized trials.
Am Heart J
; 165(2): 241-50.e4, 2013 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-23351828
16.
Comparison of Supraflex Cruz 60 µm Versus Ultimaster Tansei 80 µm Stent Struts in High Bleeding Risk PCI Patients: Study design and Rational of Compare 60/80 HBR trial.
Am J Cardiol
; 206: 230-237, 2023 Nov 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37708755
17.
Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial.
EuroIntervention
; 18(6): 492-502, 2022 Aug 19.
Artigo
Inglês
| MEDLINE | ID: mdl-35285804
18.
Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial.
EuroIntervention
; 17(16): 1340-1347, 2022 Mar 18.
Artigo
Inglês
| MEDLINE | ID: mdl-34483094
19.
Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients.
Int J Cardiol
; 334: 10-17, 2021 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33887342
20.
Ticagrelor Versus Clopidogrel in Older Patients with NSTE-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial.
J Clin Med
; 9(10)2020 Oct 12.
Artigo
Inglês
| MEDLINE | ID: mdl-33053622